EGFR and non-small cell lung carcinoma: MEK-inhibitors have been discovered to be ineffective as a monotherapy for patients diagnosed with NSCLC [100,101,102,103], although capable of potentiating the effects of the therapy with EGFR-inhibitors on EGFR-inhibitor-resistant cell lines [104,105,106].